|
| Press Releases |
|
 |
|
| Wednesday, March 23, 2022 |
|
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
| Singapore Exchange-listed Alset International Ltd (SGX Stock Code: 40V) ("Alset", the "Company" or together with its subsidiaries, the "Group) wishes to announce that the Company has plans to embark on cryptocurrency mining business through its subsidiary Alset Mining Pte. Ltd. ("Alset Mining"). more info >> |
|
| Monday, February 21, 2022 |
|
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
| Alset Capital Acquisition Corp. (the "Company") announced on February 3, 2022 the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering"). more info >> |
|
| Monday, October 5, 2020 |
|
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
| Document Security Systems, Inc. today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical") has formed a new wholly owned subsidiary, Innate Immune, Inc. ("Innate Immune"), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses. more info >> |
|
| Friday, September 18, 2020 |
|
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
| Document Security Systems, Inc. (NYSE American: DSS) today announced its wholly owned subsidiary Impact BioMedical, Inc., through its subsidiary Global BioLife, Inc., completed efficacy testing of its proprietary 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. more info >> |
|
| Friday, July 31, 2020 |
|
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. more info >> |
|
| Wednesday, June 24, 2020 |
|
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that they proved in vitro success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. more info >> |
|
| Wednesday, June 17, 2020 |
|
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020. more info >> |
|
| Monday, June 1, 2020 |
|
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies. more info >> |
|
| Friday, April 24, 2020 |
|
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
| SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). more info >> |
|
| Wednesday, March 18, 2020 |
|
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
| Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program
Feb 11, 2026 15:32 HKT/SGT
|
|
|
Changing Your Dog's Diet May Help the Planet More Than Changing Your Own, Study Finds
Feb 11, 2026 15:31 HKT/SGT
|
|
|
CleverTap Recognized as a Leader in Latest Gartner Magic Quadrant for Personalization Engines
Feb 11, 2026 15:30: JST
|
|
|
CleverTap Recognized as a Leader in Latest Gartner Magic Quadrant for Personalization Engines
Feb 11, 2026 14:30 HKT/SGT
|
|
|
Premiere of Three-Row Highlander BEV in North America
Feb 11, 2026 14:25 JST
|
|
|
研究發現：改變愛犬飲食對地球的助益可能大於改變自身飲食
Feb 11, 2026 12:42 HKT/SGT
|
|
|
The 18th Annual Global CSR & ESG Summit & Awards 2026 Arrives in Bangkok -- Igniting Asia with AI, Energy & ESG Innovation on 23 April 2026
Feb 11, 2026 12:39: JST
|
|
|
The 18th Annual Global CSR & ESG Summit & Awards 2026 Arrives in Bangkok -- Igniting Asia with AI, Energy & ESG Innovation on 23 April 2026
Feb 11, 2026 11:39 HKT/SGT
|
|
|
美國海軍陸戰隊選定通用原子航空系統公司參與MUX TACAIR協同作戰戰機計畫
Feb 11, 2026 08:00 HKT/SGT
|
|
|
美国海军陆战队选定通用原子航空系统公司参与MUX战术空中作战系统联合战斗机项目
Feb 11, 2026 08:00 HKT/SGT
|
|
|
研究发现：改变爱犬饮食对地球的益处可能大于改变自身饮食
Feb 11, 2026 07:00 HKT/SGT
|
|
|
Kincora and AngloGold Ashanti Exploration Expands and Upgrades Nevertire with Drilling Recommenced
Feb 10, 2026 19:29 HKT/SGT
|
|
|
EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong
Feb 10, 2026 18:14 HKT/SGT
|
|
|
億勝生物參展香港2026年亞太眼科學會年會（APAO 2026）强化眼科創新承諾
Feb 10, 2026 17:52 HKT/SGT
|
|
|
亿胜生物参展香港2026年亚太眼科学会年会（APAO 2026）强化眼科创新承诺
Feb 10, 2026 17:32 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
